European Journal of Cancer
Volume 46, Issue 5 , Pages 863-868 , March 2010

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations

  • Jaap Verweij

      Affiliations

    • Dept. of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Dept. of Medical Oncology, Erasmus University Medical Center, ’s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Tel.: +31 10 7034447; fax: +31 10 7034627.
    • ,
  • Laurence H. Baker

      Affiliations

    • Departments of Internal Medicine and Pharmacology, University of Michigan, Ann Arbor, USA

Received 29 December 2009 ,Accepted 14 January 2010.

References 

  1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2, 185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 1999;17:150–157
  2. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PCW, Verweij J, Blay JYPrognostic and predictive factors for outcome to first line Ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur.J.Cancer, in pre.
  3. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer. 2002;38:543–549
  4. Verweij J. Soft tissue sarcoma trials: One size no longer fits all. JCO. 2009;27:3085–3087
  5. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;3:CD003293.
  6. Göransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, et al The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene. 2009;28:270–278
  7. Grosso F, Jones Rl, Demetri GD, Judon IR, Blay JY, LeCesne A, et al Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology. 2007;8:595–602
  8. Erba E, Bergamschi B, Bassano L, Damia G, Ronzoni S, Faircloth GT, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001;37:97–105
  9. Thamm DH, Dickerson DB, Akhtar N, Lewis R, Auerbach R, Helfand SC, et al. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci. 2006;81:76–86
  10. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 2000;18:2081–2086
  11. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034–2037
  12. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Jusdon I, Thyss A, et al. Paclitaxel in patients with advance angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer. 2008;44:2433–2436
  13. Saroha , Litwin S, Von Mehren M. Retrospective review of treatment for angiosarcoma at Fox Chase Cancer Center over the past 15 years. J.Clin.Oncol. 2007;25(Suppl.):10034
  14. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori Ch. Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma. Report of 9 patients. Cancer. 2007;110(3):648–651
  15. Penel N, Bui BN, Bay JO, et al. Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group phase II trial. J.Clin. Oncol. 2007;25(June 20 Suppl.):100002
  16. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004;64(3):821–824
  17. Le Cesne A, Blay JY, Judson I, van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576–584
  18. Morgan A, Le Cesne A, Chawla S, von Mehren M, Schuetze S, Casali P, et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma after failure of prior anthracylines and ifosfamide. JCO. 2007;25(June 20 Supplement):10060
  19. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–632
  20. Maki RG, Wathen JK, Patel SR, et al. An adaptively randomized phase II study of gemcitabine and docetaxel versus gemcitabine alone in patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2007;25:2755–2763
  21. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483–3489
  22. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anti-cancer drugs. 2000;11:325–329
  23. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002;94:3225–3259
  24. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38:556–559
  25. Look KY, Sandler A, Blessing JA, Lucci JA, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecologic Oncology. 2004;92:644–647
  26. Hartmann JT, Oechsle K, Hueber J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs. 2006;24:249–253
  27. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol. 2006;29:59–61
  28. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J. Clin. Oncol. 2002;20:2824–2831
  29. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J.Clin.Oncol. 1991;9::491–498
  30. Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer. 2001;37(18):2310–2323
  31. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706–1712
  32. F. Duffaud, B. N. Bui, N. Penel, A. Cioffi, N. Isambert, J. Y. Blay, D. Cupissol, M. Jimenez, A. Rey, P. Pautier. A FNCLCC French Sarcoma Group--GETO multicenter randomized phase II study of gemcitabine versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcoma. J Clin Oncol 2008; 26 (May 20 suppl.): abstr 10511.
  33. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  34. Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339–1352
  35. Verweij J, van Oosterom AT, Blay J-Y, et al. Imatinib (STI-571) is an active agent for gastro-intestinal stromal tumors, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 2003;39:2006–2011
  36. Demetri G, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  37. Verweij J, Casali P, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004;364:1127–1134
  38. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatis gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–632
  39. Debiec-Rychter M, Sciott R, LeCesne A, et al. KIT mutations and dose selection for imatinib in patients with advances gastrointestinal stromal tumours. Eur.J.Cancer. 2006;42:1093–1103
  40. The GIST Meta-Analysis group (MetaGIST): Optimal doses of imatinib for the treatment of advanced GIST: meta-analysis on 1640 patients. J.Clin. Oncol, 2009: in press.
  41. Nielsen OS, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. The Lancet. 2002;359:1301–1307
  42. Ray-Coquard I, LeCesne A, Whelan JS, et al. A phase II study of Gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. The Oncologist;. 2008;13:467–473
  43. Korkolis DP, Liapakis IE, Vassilopoulos PP. Dermatofibrosarcoma protuberans: Clinicopathological aspects of an unusual cutaneous tumor. Anticancer Res. 2007;27:1631–1634
  44. Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, et al. Gene expression pattern and gene copy number changes in dermatofibrosarcoma protruberans. Am J Pathol. 2003;163:2383–2395
  45. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–2725
  46. S. Schuetze, P. Rutkowski, M. M. Van Glabbeke, C. Rankin, B. P. Rubin, A. Lazar, M. Debiec-Rychter, H. Gelderblom, P. Hohenberger, A. T. van Oosterom, Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2009; 27: (suppl); abstr 10520.
  47. Lebbe C, Kerob R, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicentric phase II study on 25 patients. J.Clin.Oncol. 2007;25(June 20 Suppl.):10032
  48. M. Agulnik, S. H. Okuno, M. Von Mehren, B. Jovanovic, B. Brockstein, R. S. Benjamin, A. M. Evens: An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009; 27 (suppl): abstr 10522.
  49. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J. Clin. Oncol. 2005;23:5188–5197
  50. Gordon MS, Mendelson D, Carr R, et al. A phase I trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer. 2008;113:3420–3429
  51. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008;26:5583–5588
  52. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multi-kinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043): J Clin. Oncol. 2009;27:3126–3132
  53. Maki RG, D’Adamo DR, Keohan ML, et al. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin. Oncol. 2009;27:3133–3140
  54. George S, Merriam P, Maki RG, et al. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin. Oncol. 2009;27:3154–3160
  55. Gusterson B, Cowley G, McIlhinney J, et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer. 1985;36:689–693
  56. Wallenius V, Hisaoka M, Helou K, et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol. 2000;156:821–829
  57. Motoi T, Ishida T, Kuroda M, et al. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int. 1998;48:769–775
  58. Kuhnen C, Tolnay E, Steinau HU, et al. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch. 1998;432:337–342
  59. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues To the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 2000;36:1171–1179
  60. Scappaticci FA, Marina N. New molecular targets and biological therapies in sarcomas. Cancer. Treat.Rev. 2001;27:317–326
  61. Hartog H, Wesseling J, Boezem HM, Van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: Old focus, new futures. Eur.J. Cancer. 2007;43:1895–1904
  62. Chugh R, Wathen JK, Maki RG, et al. Phase II Multicenter Trial of Imatinib in 10 Histological Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. J Clin.Oncol. 2009;27:3148–3153

PII: S0959-8049(10)00035-3

doi: 10.1016/j.ejca.2010.01.016

European Journal of Cancer
Volume 46, Issue 5 , Pages 863-868 , March 2010

Article Tools